Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Healthcare Conference ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Annual Meeting of the American Society of Clinical Oncology (ASCO), this year held in Chicago, Illinois from May 30 to June 2 ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

"It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader,” said Jesse Shefferman, Chief Executive ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...